Y-mAbs Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Y-mAbs Therapeutics

30/03/2023 22:02

* Y-mAbs Therapeutics Inc  YMAB.OQ  reported quarterly
adjusted
earnings of 3 cents​​ per share for the quarter ended in
December. The mean expectation of eight analysts for the quarter
was for a loss of 46 cents per share.
    * Revenue rose 227.6% to $31.45 million from a year ago;
analysts
expected $20.06 million. 
    * Y-mAbs Therapeutics Inc's reported EPS for the quarter was
3
cents​.
    * The mean earnings estimate of analysts had risen by
about 4.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Y-mAbs Therapeutics Inc shares had fallen by 33.6% this
quarter.
    * The company reported quarterly net income of $1.16
million.
    * Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is $9.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 30 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.46          0.03           Beat
 Sep. 30 2022      -0.71          -0.63          Beat
 Jun. 30 2022      -0.67          -0.94          Missed
 Mar. 31 2022      -0.72          -0.64          Beat